Research programme: small molecule therapeutics - AstraZeneca/ChemBridge Corporation
Latest Information Update: 30 Sep 2008
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; ChemBridge Corporation
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Unspecified
Most Recent Events
- 24 Sep 2008 AstraZeneca enters into a new research collaboration with ChemBridge